Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025

A study recently published on BMC Pulmonary Medicine compared baseline characteristics and short-term efficacy of pulmonary endarterectomy (gold standard for operable chronic thromboembolic pulmonary hypertension, removing thickened intima and organized thrombus from pulmonary arteries) vs. balloon pulmonary angioplasty (an option for inoperable chronic thromboembolic pulmonary hypertension, improving blood flow by dilating stenosed/occluded vessels without removing lesions), particularly […]

Pulmonary endarterectomy vs balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension, BMC Pulmonary Medicine, August 6, 2025 Read Post »

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025

The Research: Evidence on the predictive ability of risk assessment models for event-free survival (EFS) in patients with pulmonary arterial hypertension is scarce, say the authors of a recent study published on Pulmonary Circulation. The aim of the study was to evaluate how well three different risk assessment models predict event-free survival. The study included 411

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension, Pulmonary Circulation, July 18, 2025 Read Post »

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025

Current targeted medications for pulmonary arterial hypertension can help symptoms but have limited long-term effectiveness and often cause significant side effects and high costs. Percutaneous pulmonary artery denervation is a realtively new interventional procedure that selectively destroys sympathetic nerves to restore nerve and hormone balance in patients who don’t respond well to standard medications – see

Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report, Catheterization & Cardiovascular Interventions (CCI), July 29, 2025 Read Post »

“First five minutes”: building patient trust, a PHAWARE GLOBAL podcast, July 22, 2025 

In episode 530 of the phaware® podcast Drs. Victor Test, Deborah Levine and Rodolfo Estrada discuss CHEST’s First 5 Minutes® program, which helps medical professionals build the skills that lead to a positive relationship with patients from the get-go, creating trust and developing empathy to build rapid rapport and communicate with patients. The goal is to

“First five minutes”: building patient trust, a PHAWARE GLOBAL podcast, July 22, 2025  Read Post »

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025

A recent study titled “Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes” analysed two common health factors in people with pulmonary hypertension: inflammation and body weight. Inflammation is associated with all types of pulmonary hypertension. In the study inflammation was measured by a blood test called C-reactive protein (CRP), and body

Inflammation and Weight in Pulmonary Hypertension – Surprising Differences in Outcomes, American Journal of Respiratory and Critical Care Medicine, August 6, 2025 Read Post »

Award-Winning Singer-Songwriter Chloe Temtchine Releases New Song Featuring Hip-Hop Icon Freeway to raise awareness of pulmonary hypertension and organ transplant

Award-winning singer-songwriter Chloe Temtchine has released a new single “Heaven in the Darkest Place” featuring rapper Freeway. The song is inspired by Temtchine’s own near-death experience and life-saving double-lung transplant. Key collaborator: Freeway brings personal significance to the track – he received a kidney transplant in 2019. Broader purpose: The song serves as the official

Award-Winning Singer-Songwriter Chloe Temtchine Releases New Song Featuring Hip-Hop Icon Freeway to raise awareness of pulmonary hypertension and organ transplant Read Post »

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics”

INTRODUCTION Ever wondered how we went from completely misunderstanding blood flow for 1,400 years to performing open-heart surgery? A fascinating historical review by Prof. Adam Torbicki, published in Diagnostics (2021), reminds us that while most modern clinicians “look forward, expecting new pathophysiological pathways to be explored,” few take time “to look into the past.” Yet

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics” Read Post »

Important announcement: the date for the next World Symposium on Pulmonary Hypertension is now set!

Traditionally the World Pulmonary Hypertension Symposia series, started in Geneva in 1973 and held every 5 years after the Evian edition in 1998 (Venice 2003, Dana Point 2008, Nice 2013, Nice 2018), has marked the progresses in pulmonary hypertension science and has anticipated future developments. The published supplement including the symposia proceedings constitutes a collection

Important announcement: the date for the next World Symposium on Pulmonary Hypertension is now set! Read Post »

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025

Researchers have found two specific genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers that could help doctors detect idiopathic pulmonary arterial hypertension (IPAH) earlier and possibly guide treatment. This study, published in Scientific Reports on July 12, 2025, focused on genes linked to ferroptosis, an iron-dependent type of cell

New study finds possible diagnostic biomarkers for idiopathic pulmonary arterial hypertension, Pulmonary Hypertension News, July 12, 2025 Read Post »

«Confessions of a Tired and Lonely Caregiver», Colleen Steele, Pulmonary Hypertension News, July 21, 2025

In an article for Pulmonary Hypertension News Colleen Steele reflects on her co-experience with her husband, Brian, concerning caregiver stress syndrome, a condition of overwhelming physical, emotional, and mental fatigue, often referred to as caregiver burnout. They describe progressing through three stages of the syndrome. Stage 1 began with their son Cullen’s diagnosis of pulmonary hypertension

«Confessions of a Tired and Lonely Caregiver», Colleen Steele, Pulmonary Hypertension News, July 21, 2025 Read Post »

Gaps In Access to pulmonary hypertension care and Opportunities for improvement: A multi-site qualitative study, BMC Pulmonary Medicine, July 28, 2025

A multi-site qualitative study exploring both patient and provider perspectives on access to and timeliness of pulmonary hypertension (PH) care across the full care continuum—from symptom onset through long-term management was recently published in BMC Pulmonary Medicine. Interviews with 41 participants (21 patients, 20 providers) at three U.S. expert pulmonary hypertension centers revealed persistent delays

Gaps In Access to pulmonary hypertension care and Opportunities for improvement: A multi-site qualitative study, BMC Pulmonary Medicine, July 28, 2025 Read Post »

Roham Zamanian, MD, FCCP discusses the concept of “disease modification” in the treatment of pulmonary hypertension in a PHAWARE global association podcast

Dr. Roham Zamanian MD, FCCP, discusses the concept of “disease modification” in the treatment of pulmonary hypertension. He describes how this idea emerged from discussions with colleagues about the future of pulmonary hypertension therapies, and the potential for treatments to impact the underlying disease process beyond just reducing pulmonary artery pressures. Listen to the podcase

Roham Zamanian, MD, FCCP discusses the concept of “disease modification” in the treatment of pulmonary hypertension in a PHAWARE global association podcast Read Post »

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025

In pulmonary arterial hypertension (PAH) lung blood vessel cells grow excessively, increasing vascular resistance and ultimately leading to right heart failure. While researchers understand many molecular mechanisms behind pulmonary arterial hypertension, effective treatments remain limited. Programmed cell death (PCD) plays a crucial role in the pathogenesis of various diseases, including cancer, chronic conditions, cardiovascular disorders,

Programmed Cell Death: A Pivotal Player in Pulmonary Arterial Hypertension, European Journal of Pharmacology, July 8, 2025 Read Post »

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025

A review published on Current Opinion in Pulmonary Medicine on July 8, 2025 examines recent negative clinical trials in pulmonary arterial hypertension (PAH) research, emphasizing the valuable insights these studies provide despite their unsuccessful outcomes. The article reviews several recent negative trials testing various therapeutic approaches in pulmonary arterial hypertension, including tocilizumab (an anti-inflammatory drug),

Why negative trials in pulmonary arterial hypertension should be made public, Current Opinion in Pulmonary Medicine, July 8, 2025 Read Post »

First robotic lung transplant in Abu Dhabi, UAE, Gulf Today, July 8, 2025

Cleveland Clinic Abu Dhabi has achieved a historic milestone by performing the Gulf region’s first robotic lung transplants, making it one of only five centers worldwide to successfully complete this advanced procedure. Two patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension have undergone the surgery. These surgeries were quite complex due to pulmonary hypertension,

First robotic lung transplant in Abu Dhabi, UAE, Gulf Today, July 8, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

New study investigates reliability of point of care and remote monitoring for pulmonary arterial hypertension biomarkers NT-proBNP/BNP , Respirology, July 3, 2025

Brain natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP) serve as crucial biomarkers in pulmonary arterial hypertension (PAH). Nevertheless, test results are seldom accessible during clinical evaluations. A study published on Respirology on July 3, 2025, examined the reliability of NT-proBNP/BNP point-of-care tests (POCT) in pulmonary arterial hypertension patients and assessed the stability of

New study investigates reliability of point of care and remote monitoring for pulmonary arterial hypertension biomarkers NT-proBNP/BNP , Respirology, July 3, 2025 Read Post »

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025

A large US registry study of 1,671 patients with pulmonary arterial hypertension (PAH) over 4607 person-years of follow up found that lung transplant referrals are occurring far too infrequently and too late in the disease course. Despite professional society recommendations for early referral, only 12% of patients were referred for transplantation over the study period.

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025 Read Post »

Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications, The Patient, July 2, 2025

Jan Geissler, Founder and CEO of Patvocates, is co-author of an article titled “Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications” published on July.2, 2025 on The Patient. In a post for LinkedIn Jan says that patients and patient advocates are often missing from the author lists of scientific publications, even if

Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications, The Patient, July 2, 2025 Read Post »

TRANSLATE »
Scroll to Top